Browse through all publications from the Institute of Global Health Innovation, which our Patient Safety Research Collaboration is part of. This feed includes reports and research papers from our Centre. 

Citation

BibTex format

@article{Ward:2021:10.1038/s41467-021-21237-w,
author = {Ward, H and Atchison, C and Whitaker, M and Ainslie, KEC and Elliott, J and Okell, L and Redd, R and Ashby, D and Donnelly, C and Barclay, W and Darzi, A and Cooke, G and Riley, S and Elliott, P},
doi = {10.1038/s41467-021-21237-w},
journal = {Nature Communications},
pages = {1--8},
title = {SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.},
url = {http://dx.doi.org/10.1038/s41467-021-21237-w},
volume = {12},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - England has experienced a large outbreak of SARS-CoV-2, disproportionately affecting people from disadvantaged and ethnic minority communities. It is unclear how much of this excess is due to differences in exposure associated with structural inequalities. Here we  report from the REal-time Assessment of Community Transmission-2 (REACT-2) national  study of over 100,000 people. After adjusting for test characteristics and re-weighting to the population, overall antibody prevalence is 6.0% (95% CI: 5.8-6.1). An estimated 3.4 million people had developed antibodies to SARS-CoV-2 by mid-July 2020. Prevalence is two- to three-fold higher among health and care workers compared with non-essential workers, and in people of Black or South Asian than white ethnicity, while age- and sex-specific infection  fatality ratios are similar across ethnicities. Our results indicate that higher hospitalisation and  mortality from COVID-19 in minority ethnic groups may reflect higher rates of infection  rather than differential experience of disease or care.
AU  - Ward,H
AU  - Atchison,C
AU  - Whitaker,M
AU  - Ainslie,KEC
AU  - Elliott,J
AU  - Okell,L
AU  - Redd,R
AU  - Ashby,D
AU  - Donnelly,C
AU  - Barclay,W
AU  - Darzi,A
AU  - Cooke,G
AU  - Riley,S
AU  - Elliott,P
DO  - 10.1038/s41467-021-21237-w
EP  - 8
PY  - 2021///
SN  - 2041-1723
SP  - 1
TI  - SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic.
T2  - Nature Communications
UR  - http://dx.doi.org/10.1038/s41467-021-21237-w
UR  - https://www.nature.com/articles/s41467-021-21237-w
UR  - http://hdl.handle.net/10044/1/85566
VL  - 12
ER  -
Download

NIHR logo